Aptamers and antibodies are both molecular recognition tools—they bind targets with high specificity and affinity—but they come from very different histories. Antibodies emerged from immunology and serum therapy, while aptamers grew out of in vitro evolution and nucleic-acid chemistry. Understanding their origins helps explain why they behave differently in diagnostics, research, and therapeutics. 1) What Antibodies Are—and Why Their History Matters Antibodies are proteins produced by the immune system that recognize antigens. Their “history” is tightly linked to the birth of modern immunology: early observations that blood serum could protect against infection eventually led to the concept of specific “anti-bodies” as functional components of immunity. Over the 20th century, progress in structural biology and molecular genetics clarified how antibodies achieve both diversity and specificity, culminating in technologies that made antibodies reliable lab and industrial tools. Key turning point: monoclonal antibodies A major leap occurred in the 1970s with the development of methods to produce monoclonal antibodies—antibodies of single, defined specificity that could be generated reproducibly and at scale. This transformed antibodies from biological curiosities into standardized reagents for diagnostics and targeted therapy. 2) What Aptamers Are—and How They Were Discovered Aptamers are short, single-stranded nucleic…
What “SELEX Aptamer Selection” Means SELEX stands for Systematic Evolution of Ligands by Exponential Enrichment. In plain terms, SELEX aptamer selectionis an iterative laboratory workflow that starts with a huge pool of random DNA or RNA sequences and repeatedly enriches the fraction that binds a chosen target with high affinity and specificity. The “winners” are called aptamers—single-stranded nucleic acids that fold into 3D shapes capable of target recognition, often compared to “chemical antibodies,” but made by selection and synthesis rather than immune systems. Core Concept: Darwinian Evolution in a Test Tube SELEX is essentially variation + selection + amplification: Variation: Begin with a randomized oligonucleotide library (often ~10^13–10^16 unique sequences). Selection: Expose the library to the target; keep sequences that bind. Amplification: PCR (or RT-PCR for RNA workflows) amplifies binders to create the next-round pool. Increasing stringency: Each round tightens conditions (less target, harsher washes, more competitors), enriching the best binders over multiple cycles. Most conventional SELEX workflows run multiple rounds (often roughly 6–15) before candidates are sequenced and characterized. The Classic SELEX Workflow (Step-by-Step, With the “Why”) 1) Library design (the “starting universe”) A typical library contains: A random region (e.g., N30–N60) that can…
